Anti-PD1-induced psoriasis: a study of 21 patients-Reference-Cited by-同舟云学术

Anti-PD1-induced psoriasis: a study of 21 patients

Published:2016-11-07 Issue:5 Volume:31 Page:e254-e257
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Bonigen J.¹,Raynaud-Donzel C.²,Hureaux J.³,Kramkimel N.⁴,Blom A.⁵,Jeudy G.⁶,Breton A.-L.⁷,Hubiche T.⁸,Bedane C.⁹,Legoupil D.¹⁰,Pham-Ledard A.¹¹,Charles J.¹²,Pérol M.¹³,Gérard E.¹¹,Combemale P.¹⁴,Bonnet D.⁵,Sigal M.-L.¹,Mahé E.¹,

Affiliation:

1. Service de Dermatologie; Hôpital Victor Dupouy; Argenteuil France

2. Service de Pneumologie; Hôpital Victor Dupouy; Argenteuil France

3. Service de Pneumologie; Centre Hospitalier Universitaire; Angers France

4. Service de Dermatologie; Hôpital Cochin; Assistance Publique-Hôpitaux de Paris; Paris France

5. Service de Dermatologie Générale et Oncologique; Centre Hospitalier Universitaire Ambroise Paré; Assistance Publique-Hôpitaux de Paris; Boulogne-Billancourt France

6. Service de Dermatologie; Centre Hospitalier Universitaire François Mitterrand; Dijon France

7. Service de Dermatologie; Centre Hospitalier Universitaire de Lyon Sud; Lyon France

8. Unité de Dermatologie Infectiologie; Centre Hospitalier Intercommunal de Fréjus/Saint-Raphaël; Fréjus France

9. Service de Dermatologie; Centre Hospitalier Universitaire de Limoges; Limoges France

10. Service de Dermatologie; Centre Hospitalier Régional et Universitaire de Brest; Brest France

11. Service de Dermatologie; Centre Hospitalier Universitaire de Bordeaux; Bordeaux France

12. Service de Dermatologie; CHU Grenoble; Grenoble France

13. Département de Cancérologie Médicale; Centre Léon Bérard; Lyon France

14. Unité d'Onco-Dermatolgie; Centre Léon Bérard; Lyon France

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jdv.14011/fullpdf

Reference8 articles.

1. Nivolumab in previously untreated melanoma without BRAF mutation;Robert;N Engl J Med,2015

2. Safety, activity, and immune correlates of Anti-PD1 antibody in Cancer;Topalian;N Engl J Med,2012

3. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial;Robert;Lancet,2014

4. Immune targeting in breast cancer;Cimino-Mathews;Oncology (Williston Park),2015

5. Occurrence of psoriasiform eruption during nivolumab therapy for primary oral mucosal melanoma;Ohtsuka;JAMA Dermatol,2015

Cited by 152 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune Checkpoint Inhibitor-Induced Psoriasis;Dermatologic Clinics;2024-07

2. CACA guidelines for holistic integrative management of anticancer treatment - induced cutaneous adverse events;Holistic Integrative Oncology;2024-06-28

3. Immune-related dermatological adverse events of antitumor immunotherapy with PD-1, PD-L1, CTLA-4 inhibitors;Russian Journal of Skin and Venereal Diseases;2024-05-14

4. Risk Factors for Psoriasis Flares: A Narrative Review;Psoriasis: Targets and Therapy;2024-05

5. Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy;Journal for ImmunoTherapy of Cancer;2024-04